Simultaneous silencing of XIAP and survivin causes partial mesenchymal-epithelial transition of human pancreatic cancer cells via the PTEN/PI3K/Akt pathway

Yi,Xiao‑Ping; Han,Tong; Li,Yi‑Xiong; Long,Xue‑Ying; Li,Wen‑Zheng

doi:10.3892/mmr.2015.3380

Simultaneous silencing of XIAP and survivin causes partial mesenchymal-epithelial transition of human pancreatic cancer cells via the PTEN/PI3K/Akt pathway

Authors:
- Xiao‑Ping Yi
- Tong Han
- Yi‑Xiong Li
- Xue‑Ying Long
- Wen‑Zheng Li
View Affiliations

Affiliations: Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of General Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: February 20, 2015 https://doi.org/10.3892/mmr.2015.3380
Pages: 601-608

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer has one of the highest mortality rates among malignant tumors and is characterized by rapid invasion, early metastasis and chemoresistance. X‑linked inhibitor of apoptosis (XIAP) and survivin are two of the most important members of the IAP family. Previous studies have shown that XIAP and survivin were overexpressed in pancreatic cancer and were closely associated with cell proliferation and chemoresistance to gemcitabine. In the present study, stable inhibition of XIAP and survivin in Panc‑1 cells was performed using lentivirus‑carried short hairpin RNAs. The expression of XIAP, survivin, E‑cadherin, Slug, phosphatase and tensin homolog (PTEN) and phosphorylated Akt was then measured. In addition, cell proliferation, apoptosis, invasion and migration were assessed. The results showed that stable inhibition of XIAP and survivin expression in Panc‑1 cells significantly reduced cell proliferation, increased apoptosis and partially reversed the epithelial‑mesenchymal transition (EMT). Furthermore, the results of the present study demonstrated that the partial reversal of the EMT was accompanied by inhibited cell invasion and migration as well as increased chemosensitivity to gemcitabine in pancreatic cancer cells; this was indicated to be mediated via the PTEN/phosphatidylinositol 3-kinase/Akt signaling pathway. In conclusion, these results suggested that simultaneous inhibition of XIAP and survivin may be a promising strategy for the treatment of pancreatic cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1710. 2010. View Article : Google Scholar : PubMed/NCBI
3	Muniraj T, Jamidar PA and Aslanian HR: Pancreatic cancer: a comprehensive review and update. Dis Mon. 59:368–402. 2013. View Article : Google Scholar : PubMed/NCBI
4	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
5	Wei Y, Fan T and Yu M: Inhibitor of apoptosis proteins and apoptosis. Acta Biochim Biophys Sin (Shanghai). 40:278–288. 2008. View Article : Google Scholar
6	Silke J and Meier P: Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Cold Spring Harb Perspect Biol. 5:2013. View Article : Google Scholar : PubMed/NCBI
7	Mehrotra S, Languino LR, Raskett CM, et al: IAP regulation of metastasis. Cancer Cell. 17:53–64. 2010. View Article : Google Scholar : PubMed/NCBI
8	Jiang C, Tan T, Yi XP, et al: Lentivirus-mediated shRNA targeting XIAP and survivin inhibit SW1990 pancreatic cancer cell proliferation in vitro and in vivo. Mol Med Rep. 4:667–674. 2011.PubMed/NCBI
9	Krepela E, Dankova P, Moravcikova E, et al: Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol. 35:1449–1462. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
11	Arumugam T, Ramachandran V, Fournier KF, et al: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828. 2009. View Article : Google Scholar : PubMed/NCBI
12	Iwatsuki M, Mimori K, Yokobori T, et al: Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 101:293–299. 2010. View Article : Google Scholar
13	Hannon GJ: RNA interference. Nature. 418:244–251. 2002. View Article : Google Scholar : PubMed/NCBI
14	Tonomura H, Takahashi KA, Mazda O, et al: Glutamine protects articular chondrocytes from heat stress and NO-induced apoptosis with HSP70 expression. Osteoarthritis Cartilage. 14:545–553. 2006. View Article : Google Scholar : PubMed/NCBI
15	LaCasse EC, Mahoney DJ, Cheung HH, et al: IAP-targeted therapies for cancer. Oncogene. 27:6252–6275. 2008. View Article : Google Scholar : PubMed/NCBI
16	Urrutia R: The IAP: more international than ever. Pancreatology. 9:III–IV. 2009.
17	Thiery JP, Acloque H, Huang RYJ and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
18	Wang Z, Li Y, Kong D, et al: Acquisition of epithelial-mesen-chymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
19	Deng Y, Wang CC, Choy KW, et al: Therapeutic potentials of gene silencing by RNA interference: Principles, challenges, and new strategies. Gene. 538:217–227. 2014. View Article : Google Scholar : PubMed/NCBI
20	Jiang G, Li J, Zeng Z and Xian L: Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther. 5:435–440. 2006. View Article : Google Scholar : PubMed/NCBI
21	Kunze D, Kraemer K, Erdmann K, et al: Simultaneous siRNA-mediated knockdown of antiapoptotic BCL2, Bcl-xL, XIAP and survivin in bladder cancer cells. Int J Oncol. 41:1271–1277. 2012.PubMed/NCBI
22	Ravet E, Lulka H, Gross F, et al: Using lentiviral vectors for efficient pancreatic cancer gene therapy. Cancer Gene Ther. 17:315–324. 2010. View Article : Google Scholar
23	Ruckert F, Samm N, Lehner AK, et al: Simultaneous gene silencing of Bcl-2, XIAP and Survivin re-sensitizes pancreatic cancer cells towards apoptosis. Bmc Cancer. 10:3792010. View Article : Google Scholar : PubMed/NCBI
24	Min C, Eddy SF, Sherr DH, et al: NF-κB and epithelial to mesenchymal transition of cancer. J Cell Biochem. 104:733–744. 2008. View Article : Google Scholar : PubMed/NCBI
25	Carnero A, Blanco-Aparicio C, Renner O, et al: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI
26	Jiang BH and Liu LZ: PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res. 102:19–65. 2009.PubMed/NCBI
27	Hafsi S, Pezzino FM, Candido S, et al: Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Int J Oncol. 40:639–644. 2012.
28	Ma J, Sawai H, Ochi N, et al: PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells. Mol Cell Biochem. 331:161–171. 2009. View Article : Google Scholar : PubMed/NCBI
29	Chen X, Liao J, Lu Y, et al: Activation of the PI3K/Akt pathway mediates bone morphogenetic protein 2-induced invasion of pancreatic cancer cells Panc-1. Pathol Oncol Res. 17:257–261. 2011. View Article : Google Scholar
30	Parsons CM, Muilenburg D, Bowles TL, et al: The role of Akt activation in the response to chemotherapy in pancreatic cancer. Anticancer Res. 30:3279–3289. 2010.PubMed/NCBI